LEIDEN, NETHERLANDS--(Marketwire - February 07, 2008) - OctoPlus N.V. (“OctoPlus” or the “Company”) (Euronext: OCTO), the drug delivery and development company, announces today the commencement of patient dosing in a Phase IIa study in the United States with Locteron®, its controlled-release formulation of alfa interferon for treatment of chronic hepatitis C (HCV). This study will expand upon the favorable results of the recently completed SELECT-1 Phase IIa study in Europe, which were presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) conference in November. The study is being conducted under an Investigational New Drug (IND) application filed with the US Food and Drug Administration.
